A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 3,801–3,900 of 3,965
Nakaphan, P., Shotelersuk, V., Pajareya, P., Siranart, N., & Ifteqar, S. (2026) · Clinical Rheumatology · doi:10.1007/s10067-026-08043-9
Extent of alveolar collapse in expiratory CT as a prognostic marker in idiopathic pulmonary fibrosis
Scharm, S. C., Schaefer‐Prokop, C. M., Schreuder, A., Ehmig, J., Hunkemöller, A. M., Fuge, J., Seeliger, B., Schupp, J. C., Wacker, F. K., & Shin, H. (2026) · PLoS ONE · doi:10.1371/journal.pone.0345308
“In patients with progressive fibrosis and worsening lung function, antifibrotic medications are recommended to potentially slow down the disease [3,4].”
Nayak, B. B., Rajesh, R., Teppan, J., Gogg, T., & Böhm, E. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1784434
Zaizen, M., Zaizen, Y., Tsumura, K., Chikasue, T., Nagata, S., 誠之, 渡., Okamoto, M., Tominaga, M., Tabata, K., Tanoue, S., et al. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101417
Agent-Based Modeling of Idiopathic Lung Fibrosis and Mechanistic TreatmentsPreprint
Gunputh, N. D., Kilikian, E., Miranda, C., PEIRCE, S. M., & Versypt, A. N. F. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.22.713503
Gul, A., Zhong, Y., Aili, M., Xie, C. H., Talifu, A., Huo, S., Kuerban, Y., Yalkun, M., Li, Z. J., & Dong, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-45457-6 · Cited by 1
Clonal Hematopoiesis Instructs Maladaptive Tissue Repair to Promote FibrosisPreprint
Li, D., Viñado, A. C., García‐Olloqui, P., Montesi, S. B., Shea, B. S., Christian, L., Vázquez-Urio, I., Aguirre-Ruiz, P., Ariceta, B., Neubert, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.24.710438
Bao, H., Jian, Y., Penaloza-Ramos, C. M., Kanakapura, M., Deng, Z., Xuan, J., & Zhao, H. (2026) · Pharmacoeconomics and Policy · doi:10.1016/j.pharp.2026.03.005
Cottin, V., Crestani, B., Planès, C., Chambellan, A., Charloux, A., Degano, B., Gille, T., Glérant, J., Jouneau, S., Mewton, N., et al. (2026) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2026.101266
Trabadelo, H. (2026) · Research Square · doi:10.21203/rs.3.rs-9237519/v1
Brugière, O., & Giménez, B. S. (2026) · European Respiratory Journal · doi:10.1183/13993003.02412-2025
Philippot, Q., Guyard, A., Debray, M., & Crestani, B. (2026) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(26)51690-8
Étude mécanistique de la fibrose interstitielle rénale et essai de preuve de concept thérapeutique
Gaillard, F. (2018) · theses.fr (ABES) · doi:10.70675/72e11c14zcc9fz4acdzbb83z2368f5351848 · Cited by 1
Challenging the status quo for therapeutic clinical trials in fibrotic interstitial lung diseases
Kulkarni, T., Funke-Chambour, M., Jones, S., Rivera‐Ortega, P., & Montesi, S. B. (2026) · Thorax · doi:10.1136/thorax-2024-222057
Survival of patients with newly diagnosed IPF at the time of respiratory-related hospitalization
Yamazaki, R., Nishiyama, O., Kawabata, Y., Yosikawa, K., & Matsumoto, H. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101413
Bellamri, N. (2019) · theses.fr (ABES) · doi:10.70675/61c916f9za0f1z4c86z8499zbe1cb4cf0b5b · Cited by 1
Treatable traits in interstitial lung disease: towards precision medicine
Avitzur, N., Marinescu, D.-C., Churg, A., Goobie, G. C., Hague, C. J., Müller, N. L., Wright, J. L., & Ryerson, C. J. (2026) · Thorax · doi:10.1136/thorax-2024-222058
Traitement de la fibrose pulmonaire idiopathique : Rôle de TRIM33 et de l’inhibition d’HSPB5
Boutanquoi, P. (2019) · theses.fr (ABES) · doi:10.70675/968e196dz45c0z4010za2dez22d692e030cc
Les rôles tubulaires et macrophagiques de la périostine dans les maladies rénales aigues
Kormann, R. (2018) · theses.fr (ABES) · doi:10.70675/e7200627za1dbz4d4ezbd37zcd1b9fd4c6b3
Косолапов, В. А., & Спасов, А. А. (2026) · Journal of Volgograd State Medical University · doi:10.19163/1994-9480-2026-23-1-10-17
Rôle des FGFs endocrines et leurs récepteurs au cours de la fibrose pulmonaire idiopathique
Ghanem, M. (2023) · theses.fr (ABES) · doi:10.70675/fd0d64f8zacf4z4856z9b1az66d4df37a332
Menon, A. A., & Ghosh, A. J. (2026) · CHEST Journal · doi:10.1016/j.chest.2025.10.013
Selection for Function in Early Life: Implications for Early‐Onset Pathologies
Asselin, K., Dujon, A. M., Capp, J., Lemaître, J., Pirard, F., Vaiman, D., Újvári, B., Pujol, P., DeGregori, J. V., Nedelcu, A. M., et al. (2026) · Evolutionary Applications · doi:10.1111/eva.70226 · Cited by 1
Li, Z., Hong, L., Lv, X., Yang, S., Ye, F., Huang, L., Jiang, S., & Zhao, H. (2026) · Communications Biology · doi:10.1038/s42003-026-10033-1
Is there more to change in forced vital capacity in pulmonary fibrosis trials?
Andrei, A., & Kass, D. J. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag171
Respiratory diseases: Innovations in early diagnosis
Kumari, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33263-0.00008-5
A syndromic framework for progressive pulmonary fibrosis
Perrotta, F., Luppi, F., Sebastiani, M., & Bianco, A. (2026) · Respiratory Research · doi:10.1186/s12931-026-03649-8 · Cited by 1
Tonelli, R., Turchiano, M. G., Moretti, A., Andrisani, D., Gozzi, F., Raineri, G., Samarelli, A. V., Andolfi, F., Ruggieri, V., Clini, E. M., et al. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04343-9 · Cited by 1
Mansour, G. K., Hajjar, A. W., & Sukkarieh, H. H. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1748453 · Cited by 1
Xu, H., Meier, E., Chhabria, M., DeDent, A. M., Hui, S. L., Zhang, Z., & Boente, R. (2026) · CHEST Journal · doi:10.1016/j.chest.2026.03.040
Morsi, K., Abdelmoneim, T. K., Youssef, N. A., Elzayat, E. M., Magdeldin, S., & Amr, D. (2026) · Scientific Reports · doi:10.1038/s41598-026-46691-8
Aoyama, J., Taniuchi, N., Saito, S., Nishima, S., Okamura, K., Tanaka, T., Tanaka, Y., Kamio, K., Atsumi, K., Hirose, T., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9355521/v1
Okuno, D., Sakamoto, N., Akiyama, Y., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1809175
“Current pharmacologic interventions for IPF, including nintedanib and pirfenidone, modestly slow disease progression and improve patient outcomes; however, they fail to reverse established fibrosis (King et al., 2014; Raghu et al., 2022; Richeldi et al., 2014).”
Jouneau, S., Prévot, G., Constantin, A., Agard, C., Gauthier, S., Bouvard, C., Guillotin, M., Gorayeb, C., Hakibilen, C., & Aguilaniu, B. (2026) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2026.03.001
Chi, E., Holland, A. E., Hill, C. J., Goh, N. S. L., Glaspole, I., McDonald, C. F., & Dowman, L. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.108867
Self-citationShim, D. H., Kim, M. J., Chung, H. W., Kim, M. N., Sohn, M. H., Lee, S. K., Kim, I., Lee, C. G., Elias, J. A., Park, J. H., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050554 · Cited by 1
Zhao, X., Ding, W., Zhang, L., Cai, Q., Lu, Z., Huang, W., Xie, W., & Kong, H. (2026) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073468105260421052108
Design, synthesis, and biological evaluation of ALK5 PROTAC degraders for pulmonary fibrosis
Yue, L., Li, Y., Gan, C., Sun, M., Deng, C., Xue, T., Xie, Y., Liu, H., Liu, Z., & Ye, T. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109945
From empiricism to precision: SHINE strategy in anti-fibrotic drug discovery
Huang, W. Z., & Cong, Z. (2026) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2026.05.002
From Inflammation to Precision Medicine: Mechanistic Insights into Asthma, COPD, and IPF
Ghrairi, N., Elhechmi, Y. Z., & Saad, S. B. (2026) · Biomedicines · doi:10.3390/biomedicines14051055 · Cited by 2
“Beyond single targets, other emerging approaches include phosphodiesterase-4 inhibitors, additional tyrosine kinase inhibitors, integrin antagonists ( α v β 6, α v β 1), and inhaled prostacyclin analogues such as treprostinil, currently under investigation in the TETON phase III program [65].”
Trends in antifibrotic approvals for interstitial lung disease in Ontario, Canada
Luu, B., & Fidler, L. (2026) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2026.2655671
Rentosertib: A TNIK inhibitor in clinical trials for idiopathic pulmonary fibrosis
Meng, S., & Zhao, J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45105-8.00015-9
Tomassen, M. L., Nijman, S. F. M., Nossent, E. J., Simons, I. A., Dickhoff, C., Mets, O. M., Radonic, T., Boerrigter, B. G., van Dorp, M., Heineman, D. J., et al. (2026) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2026.111588 · Cited by 1
Advances in pharmacotherapy for fibrotic interstitial lung disease
Feng, X., Deng, M., Miao, J., Zheng, Z., & Hou, G. (2026) · Medical Review · doi:10.1515/mr-2025-0086 · Cited by 1
Tukhovskaya, E. A., Palikova, Y. A., Severyukhina, M. S., Ismailova, A. M., Паликов, В. А., Слащева, Г. А., Borozdina, N. A., Mikhaylov, E. S., Kravchenko, I. N., Kazakov, V. A., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1822289
“Our study also demonstrated an increase in BALF lymphocyte content: sixfold during the acute inflammatory phase and 1.5–2 times during the % (21, 63) and reducing disease exacerbations (64).”
InfluentialXu, J., Liu, X., Liang, X., Cai, X., & Qian, W. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04342-8 · Cited by 2
A patent review of LPAR1 antagonists (2010 – present)
Zhao, J., Li, Y. X., Zheng, W., Liu, Y., Yang, Y., Leng, Y., Wei, S., Lou, J., Shang, X., & Tang, D. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2671884
Stella, G. M., Carrozzo, V. M., Lettieri, S., et al. (2026) · Multidisciplinary Respiratory Medicine · doi:10.5826/mrm.2026.1072
The changing face of lung transplant candidates
Leuzzi, F. R., Clausen, E. S., & Dilling, D. F. (2026) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001273
Bui, P., Onge, E. S., Sotolongo-Miranda, H., & Trabulsi, T. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261447319
Newton, C. A. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag237
Chen, G., Sheng, G., Wu, K., Jin, T., Jiang, Q., Guo, T., Chen, Y., Yin, H., Zhang, G., Shen, Z., et al. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s610536
Objective clinical scoring system and diagnostic variability in idiopathic pulmonary fibrosis
Abecassis, C., Pastré, J., Case, A., et al. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04293-0
Self-citationMohamed, S. R., Selim, S. A., Mohamed, S. A., & Abdelfadeel, K. (2026) · Ultrastructural Pathology · doi:10.1080/01913123.2026.2668409
Lactic acid and Lactylation in the Progression of Pulmonary Fibrosis
Wang, F., Jiang, M., Zhu, L., Liu, J., Tang, J., Jin, X., Liu, H., Cheng, Z., Wang, Z., Liu, R., et al. (2026) · BIO Integration · doi:10.15212/bioi-2026-0009 · Cited by 1
Sun, C.-Y., Yang, W., Shen, H., Yu, W.-K., Chen, W.-C., & Yang, K. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s569219
Kølner-Augustson, L., Altraja, A., Bendstrup, E. M., Bradding, P., Østergård, N. M., Wilson, A. C., Simonsen, U., & Hilberg, O. (2026) · Diagnostics · doi:10.3390/diagnostics16111649
Carballo, A. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1779725
Wang, S., Han, R., Guo, R., Wang, C., Kang, W., Liu, J., & Long, C. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl49465
Justet, A., Poletti, V. E., Coarfa, C., Hussein, N. A., Adams, T. S., Waich, A., Balayev, A., Yan, X., Cai, Z., Moussa, F., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.27.727792
Pulmonary fibrosis: evolving therapeutic pipeline
Shannon, L., Islam, S., Hilary, B., Murphy, G., Bailey, S., Rooney, R., & Chaudhuri, N. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-001886
Hirsch, T. I., Miller, W. P., Tsikis, S. T., Arévalo-Alquichire, S., Kaplan, B. A., Barake, K. W., Gunawan, A. L., Vanderleest, T. E., Vijikumar, A., Sanchez-Suarez, J., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-55553-2
Improved time to antifibrotic approval using an online drug application portal
Luu, B., & Fidler, L. (2026) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2026.2668051
Lee, J. M., Kim, K. T., Lee, C., & Hwang, H. S. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18060668
“Nevertheless, neither therapy halts disease progression in most patients, and treatment is frequently limited by gastrointestinal and hepatic adverse effects, poor tolerability, and high cost, leading to dose reduction or discontinuation in real-world settings [15–17].”
Yang, J., Fee, R. M., Steffens, A., Le, L., Bui, B. H., & Borah, B. J. (2026) · Journal of health economics and outcomes research · doi:10.36469/jheor.2026.161503
Chee, M., Khor, Y. H., Jackson, D., Cooper, W., D'Costa, J., de Boer, S., Edwards, A., Ellis, S. J., Gabbay, E., Gallagher, H., et al. (2026) · Internal Medicine Journal · doi:10.1111/imj.70490
Self-citationZhang, S.-M., Huang, M.-Z., Wang, Y.-W., Wang, X.-F., Ding, Y., Li, J. Q., Zou, X.-M., & Ma, C. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.108946 · Cited by 2
Canals-Domenech, C., Vicens‐Zygmunt, V., Bermudo, G., Murillo, E., Rivera‐Ortega, P., Wijsenbeek, M. S., Antoniou, K., Bonella, F., Rusell, A.-M., Renzoni, E., et al. (2026) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2026.05.024
Wang, X., Li, Y., Zhao, L., Zhang, X., Liu, M., & Dai, H. (2026) · The Clinical Respiratory Journal · doi:10.1111/crj.70202
CTHRC1: a serum biomarker for a pathological fibroblast in IPF
Khatri, A., & Todd, J. L. (2026) · Thorax · doi:10.1136/thorax-2026-225250
Man, J., Zhang, X., Zhang, Y., Zheng, Y., Wang, H., Yuan, Y., & Xie, X. (2026) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70527
“Although PFD and nintedanib are clinically approved for the treatment of pulmonary fibrosis, the therapeutic efficacy is limited, associated with severe adverse effects, such as gastrointestinal disturbances, rash, and photosensitivity [ 6–8 ].”
Therapeutic effect and mechanism of pirfenidone in bladder fibrosis after spinal cord injury
Huang, X., Zhang, J., Hou, Y., Yuan, F., Liu, P., Guo, S., Bai, K., & Sun, J. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178930 · Cited by 1
S100A4 Orchestrates Fibroblast Fate to Drive Fibrotic Remodeling
Li, S., Cai, B., Zhang, X., Cai, G., Zhou, Y., Wagener, B. M., & Ding, Q. (2026) · The FASEB Journal · doi:10.1096/fj.202600886r
Park, S., Jung, W., Jeon, J., et al. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.05.013
Global landscape for pulmonary fibrosis treatment: a data-driven perspective from clinical trials
Zhao, C., Song, C., Zhou, Y., Luo, J., Zheng, S., Li, X., Dang, Y., Yang, N., & Kong, J. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04340-w
Gao, F., Fung, A. A., Zhang, D., Lou, X., Nam, J., Yang, M., Tian, X., Farzad, N., Wang, D., Li, G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.18.732453
The role of macrophage-myofibroblast transition in the pathogenesis of multi-organ fibrosis
Guo, C., Cao, R., Liao, L., Zhao, J., Wang, T., Li, J. J., Zhang, Y., & Li, H. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103702
Kim, D. K. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.26.0058
Translational Insights into Phytoceutical-Based Pulmonary Drug Delivery for Fibrosis Therapy
Joshi, D., Shukla, P., & Vishwakarma, S. (2026) · International Journal of Newgen Research in Pharmacy & Healthcare · doi:10.61554/ijnrph.v4i1.2026.215
Targeted DNA triplex-forming oligonucleotide liposome for pulmonary fibrosis gene therapy
Xu, J., Xie, Y., Luo, Q., Ren, Y., Wang, J., Qin, C., Li, P., Liu, Y., Cheng, Y., Jiang, M., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102909
Sun, J., Yu, D., Chen, C., Yang, J., Li, J., Luo, R., Li, L., Jin, S., Liu, Z., Li, Z., et al. (2026) · Nano Energy · doi:10.1016/j.nanoen.2026.112174
Stiefer, A., Howard, A., Neely, M. L., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10007120/v1
Yabuuchi, H., Sagiyama, K., Tsubouchi, K., Hashisako, M., Takano, T., Yamasaki, Y., Hida, T., Hino, T., Tashiro, K., Nishizawa, N., et al. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.109022
Fay, C. (2026) · Academic Medicine & Surgery · doi:10.62186/001c.163657
Koschel, D., Behr, J., & Bonella, F. (2026) · Pneumologie · doi:10.1055/a-2883-1874
Fibrotic chronic eosinophilic pneumonia: from inflammation to fibrosis and therapeutic implications
Previtero, D., Castelli, G., Padrin, Y., Scalvenzi, F., Ruzzon, I., Cocconcelli, E., Tinè, M., Balestro, E., Padoan, R., Caminati, M., et al. (2026) · European Respiratory Review · doi:10.1183/16000617.0076-2026 · Cited by 1
Arakeep, H. M., Emam, W., Mohammed, A. R., Sedira, M. H., Awad, M. M., Aboalsoud, A., El‐Shaer, R. A. A., Aboshanady, A. M. M., & AbuoHashish, N. A. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12246-3
Mitoception: A Novel Strategy to Alleviate Pulmonary Fibrosis
Bhogoju, S., Patel, P., Kapur, N., Kunjadia, P. D., Aloysius, A., Esoe, D.-P. I., Sturgill, J., Brainson, C. F., Chaiswing, L., Sullivan, P. G., et al. (2026) · Biology · doi:10.3390/biology15141112
Sharata, E. E., Abdelnaser, M., Bakry, T., Hassan, M. A., William, N. S., Yasser, V., Rashad, M. S., Tadres, K. E., & Mohyeldin, R. H. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05688-w · Cited by 1
Pirfenidone Injection to Prevent Vocal Fold Scarring in a Canine Model: A Pilot Preclinical Study
Ji, J.-Y., Han, Y. B., Kim, S. Y., et al. (2026) · Journal of Voice · doi:10.1016/j.jvoice.2026.05.018
Precision Modulation of the PDE4 Pathway: The Emerging Role of Nerandomilast in Pulmonary Fibrosis
Bishop, K. N., Santana, J. M., Dietrich, E., et al. (2026) · Journal of Pharmacy Technology · doi:10.1177/87551225261466572
Chen, B., Wang, R., Zhao, Y. C., Qian, Y., Wang, G., Fan, Q., & Bai, G. (2026) · PLoS ONE · doi:10.1371/journal.pone.0353062
“It can intervene in the mRNA transcription process of TGF-β , reduce TGF-β expression level, and block the downstream signaling pathway of TGF-β [30,31].”
Pulmonary fibrosis and the TGF-β signaling axis: Advances in targeted therapeutics
Wang, Y., Xu, Y., Zhang, Y., Wang, B., Liu, X., & Zhang, H. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179174 · Cited by 1
Paliogiannis, P., Zoroddu, S., Fois, S., Scala, C., Zinellu, E., Mangoni, A. A., Carru, C., Pirina, P., Zinellu, A., & Fois, A. G. (2026) · Antioxidants · doi:10.3390/antiox15080923
Zhang, X., Chen, Y., Cai, S., Ye, C., Hu, Z., Zhang, Z., Wang, Y., Hu, Q., & Dong, L. (2026) · Clinical Rheumatology · doi:10.1007/s10067-026-08315-4
Decorin and IL-10 co-overexpression in BMDMSCs attenuates pulmonary fibrosis – an experimental study
Yue, Y., Lin, K., Fang, W.-F., Shao, P., Huang, C., Chen, Y., Wang, Y.-T., Yip, H., & Lee, M. S.-S. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000005530
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.